Abstract
Nebivolol is a highly β 1 -selective blocker indicated for the treatment of essential hypertension and stabilized mild-to-moderate chronic cardiac failure in combination with standard therapy in elderly patients. The vasodilator effect of nebivolol is mediated through the production of nitric oxide.
Nebivolol acts favourably on endothelial dysfunction and exhibits neutral to positive effect on the metabolic profile.